The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX

The intravenous, rapidly acting P2Y12 inhibitor cangrelor reduces the rate of ischemic events during PCI with no significant increase in severe bleeding. However, the efficacy and safety of cangrelor compared with clopidogrel in patients treated with single vessel (SV)‐percutaneous coronary intervention (PCI) or multivessel (MV)‐PCI remains unexplored.

[1]  D. Faxon,et al.  Multi-vessel coronary disease and percutaneous coronary intervention , 2004, Heart.

[2]  E. Paolasso,et al.  Culprit-only or multivessel percutaneous coronary stenting in patients with non-ST-segment elevation acute coronary syndromes: one-year follow-up. , 2009, Journal of interventional cardiology.

[3]  Per Albertsson,et al.  Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). , 2013, Journal of the American College of Cardiology.

[4]  Samin K. Sharma,et al.  Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. , 2009, JACC. Cardiovascular interventions.

[5]  U. Siebert,et al.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. , 2009, The New England journal of medicine.

[6]  C. Maynard,et al.  Prevalence and Procedural Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in Patients with Diabetes and Multivessel Coronary Artery Disease , 2011, Journal of cardiac surgery.

[7]  D. Ramsdale,et al.  Effect of completeness of revascularization on clinical outcome in patients with multivessel disease presenting with unstable angina who undergo percutaneous coronary intervention. , 2004, The Journal of invasive cardiology.

[8]  Deepak L. Bhatt,et al.  Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. , 2000, Circulation.

[9]  Deepak L. Bhatt,et al.  Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report. , 2008, American heart journal.

[10]  C. Cannon,et al.  Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes. , 2002, The American journal of cardiology.

[11]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[12]  Deepak L. Bhatt,et al.  Cangrelor reduces the risk of ischemic complications in patients with single‐vessel and multi‐vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial , 2017, American heart journal.

[13]  Mandeep Singh,et al.  An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. , 2013, JACC. Cardiovascular interventions.

[14]  C. Tajer,et al.  Multivessel versus Single Vessel Angioplasty in Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Metaanalysis , 2016, PloS one.

[15]  Deepak L. Bhatt,et al.  Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. , 2016, Journal of the American College of Cardiology.

[16]  Deepak L. Bhatt,et al.  Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. , 2005, Circulation.

[17]  Deepak L. Bhatt,et al.  Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. , 2012, American heart journal.

[18]  Deepak L. Bhatt,et al.  Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial , 2018, European heart journal.